芪白平肺胶囊治疗慢性阻塞性肺疾病

目的 探讨芪白平肺胶囊治疗慢性阻塞性肺疾病（chronic obstructive pulmonary disease，COPD）合并抑郁障碍的疗效。方法 将58例COPD合并抑郁障碍患者随机分为治疗组（29例）与对照组（29例），在常规治疗基础上，治疗组与对照组分别加用芪白平肺胶囊与氟哌噻吨美利曲辛，观察两组患者血液流变性、T淋巴细胞亚群及汉密尔顿抑郁量表（Hamilton depression scale，HAMD）评分的变化。结果 治疗组在降低COPD合并抑郁患者的HAMD评分，降低全血高切、低切黏度及血浆比黏度，升高CD4+细胞百分比，降低CD8+细胞百分比方面显著优于对照组（P<0.05，或P<0.01）。结论 芪白平肺胶囊能改善COPD抑郁障碍患者血液流变性，调节T淋巴细胞亚群，降低HAMD评分，对COPD患者有较好疗效。

Therapeutic Efficacy of Qibai Pingfei Capsules in Treatment of Chronic Obstructive Pulmonary Disease Associated with Depressive Disorder: A Report of 29 Cases

Objective To investigate the therapeutic efficacy of Qibai Pingfei Capsules in the treatment of chronic obstructive pulmonary disease (COPD) associated with depressive disorder. Methods Fifty eight COPD patients with depressive disorder were randomly divided into treatment group (n=29) and control group (n=29). On the basis of conventional therapy, Qibai Pingfei Capsules and flupentixol melitracen were given to the treatment group and control group, respectively. The changes in hemorheological parameters, T lymphocyte subsets, and Hamilton depression scale (HAMD) score in both groups were observed. Results Compared with the control group, the treatment group showed significantly lower HAMD score, blood viscosity at high and low shear rates, and plasma viscosity, significantly higher CD4+ cell percentage, and significantly lower CD8+ cell percentage (P<0.05 or P<0.01). Conclusion Qibai Pingfei Capsules can improve hemorheological properties, adjust T lymphocyte subsets, and decrease HAMD score in COPD patient with depressive disorder, achieving good therapeutic efficacy.